Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 2, 2008, Pages 247-258

  Edsbäcker, Staffan ^a   Wollmer, Per ^b   Selroos, Olof ^c   Borgström, Lars ^a   Olsson, Bo ^a   Ingelf, Jarl ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Airway selectivity; Asthma; COPD; Inhaled corticosteroids; Mucociliary clearance

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; MOMETASONE FUROATE;

AREA UNDER THE CURVE; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE SEVERITY; DOSE RESPONSE; DRUG EXPOSURE; DRUG SOLUBILITY; DRUG UPTAKE; DYNAMICS; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CLEARANCE; MUCOCILIARY CLEARANCE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; BRONCHOCONSTRICTION; COUGH; HUMANS; MUCOCILIARY CLEARANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 40049086856     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.08.005     Document Type: Review

References (84)

1. Lipworth B.J., and Jackson C.M. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 23 (2000) 11-33
2. Kelly H.W. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol 91 (2003) 326-334
3. Allen D.B. Systemic effects of inhaled corticosteroids in children. Curr Opin Pediatr 16 (2004) 440-444
4. Lee D.K., and Lipworth B.J. The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease. Br J Clin Pharmacol 57 (2004) 388-392
5. Hallett C. Corticosteroid treatment of asthma: now at the crossroad. Respir Med 93 (1999) 292-294
6. Weiner P., Berar-Yanay N., Davidovich A., and Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 116 (1999) 931-934
7. Lee D.K.C., Bates C.E., Currie G.P., Cowan L.M., McFarlane L.C., and Lipworth B.J. Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. Ann Allergy Asthma Immunol 93 (2004) 253-258
8. Brutsche M.H., Brutsche I.C., Munavvar M., Langley S.J., Masterson C.M., Daley-Yates P.T., et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 356 (2000) 556-561
9. Harrison T.W., Wisniewski A., Honour J., and Tattersfield A.E. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 56 (2001) 186-191
10. Thorsson L., Edsbäcker S., Källén A., and Löfdahl C.-G. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 52 (2001) 529-538
11. Mortimer K., Harrison T.W., Tang Y., Wu K., Hochhaus G., and Tattersfield A.E. Plasma concentrations of fluticasone and budesonide following inhalation: the effect of methacholine induced airflow obstruction. Br J Clin Pharmacol 64 (2007) 439-444
12. Mortimer K.J., Harrison T.W., Tang Y., Wu K., Lewis S., Sahasranaman S., et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol 62 (2006) 412-419
13. Singh S.D., Whale C., Houghton N., Daley-Yates P., Kirby S.M., and Woodcock A. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. Br J Clin Pharmacol 55 (2003) 375-381
14. Mendes E.S., Pereira A., Danta I., Duncan R.C., and Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J 21 (2003) 989-993
15. Harrison T.W., and Tattersfield A.E. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 58 (2003) 258-260
16. Borgström L., Derom E., Ståhl E., Wåhlin-Boll E., and Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 153 (1996) 1636-1640
17. Agertoft L., and Pedersen S. Importance of inhalation device on the effect of budesonide. Arch Dis Child 69 (1993) 1301-1311
18. Busse W.W., Brazinsky S., Jacobson K., Stricker W., Schmitt K., Vanden Burgt J., et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 104 (1999) 1215-1222
19. Lawrence M., Wolfe J., Webb D.R., Chervinsky P., Kellerman D., Schaumberg J.P., et al. Efficacy of inhaled fluticasone propionate in asthma: results from topical and not from systemic activity. Am J Respir Crit Care Med 156 (1997) 744-751
20. Toogood J.H., Frankish C.W., Jennings B.H., Baskerville J.C., Borgå O., Lefcoe N.M., et al. A study of the mechanism of the antiasthmatic action of inhaled budesonide. J Allergy Clin Immunol 85 (1990) 872-880
21. Cerasoli Jr. F. Developing the ideal inhaled corticosteroid. Chest 130 1 Suppl S (2006) 54S-64S
22. Edsbäcker S. Uptake, retention, and biotransformation of corticosteroids in the lung and airways. In: Schleimer R.P., O'Byrne P.M.O., Szefler S.J., and Brattsand R. (Eds). Inhaled steroids in asthma: optimizing effects in the airways (2002), Marcel Dekker, New York 213-246
23. Borgström L., Olsson B., and Thorsson L. Degree of throat deposition can explain the variability of lung deposition of inhaled drugs. J Aerosol Med 19 (2006) 473-483
24. Borgström L. On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med 14 (2001) 281-287
25. ® in patients with acute airway obstruction and COPD, and in children with asthma: understanding the clinical importance of adequate peak inspiratory flow, high lung deposition, and low in vivo dose variability. Treat Respir Med 5 (2006) 305-315
26. Thorsson L., Kenyon C., Newman S.P., and Borgström L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharmaceut 168 (1998) 119-127
27. O'Riordan T.G., Zwang J., and Smaldone G.C. Mucociliary clearance in adult asthma. Am Rev Respir Dis 146 (1992) 598-603
28. Saari M., Vidgren M.T., Koskinen M.O., Turjanmaa V.M., Waldrep C., and Nieminen M.M. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 113 (1998) 1573-1579
29. Chung K.F., Jeyasingh K., and Snashall P.D. Influence of airway calibre on the intrapulmonary dose and distribution of inhaled aerosol in normal and asthmatic subjects. Eur Respir J 1 (1988) 890-895
30. Saari S.M., Vidgren M.T., Herrala J., Turjanma V.M.H., Koskinen M.O., and Nieminen M.M. Possibilities of formoterol to enhance the peripheral lung deposition of the inhaled liposome corticosteroids. Respir Med 96 (2002) 999-1005
31. Lucas A.M., and Douglas L.C. Principles underlying ciliary activity in the respiratory tract. II. A comparison of nasal clearance in man, monkey and other mammals. Arch Otolaryngol 20 (1934) 518-541
32. Verdugo P. Mucin exocytosis. Am Rev Respir Dis 144 (1991) S33-S37
33. Tarran R., Button B., and Boucher R.C. Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress. Annu Rev Physiol 68 (2006) 543-561
34. Tarran R., Trout L., Donaldson S.H., and Boucher R.C. Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. J Gen Physiol 127 (2006) 591-604
35. Toremalm N.H. The daily amount of tracheobronchial secretion in man: a method for continuous tracheal aspiration in laryngectomized and tracheostomized patients. Acta Otolaryngol Suppl 158 (1960) 43-53
36. Foster W.M., Langenback E.G., and Bergofsky E.H. Measurement of tracheal and bronchial mucus velocities in man: relation to lung clearance. J Appl Physiol 48 (1980) 965-971
37. West J.B. Pulmonary pathophysiology, the essentials. 4th ed (1992), Williams & Wilkins, Baltimore p. 137
38. Puchelle E., Zahm J.M., and Bertrand A. Influence of age on bronchial mucociliary transport. Scand J Respir Dis 60 (1979) 307-311
39. Hybbinette J.C., and Mercke U. Effects of sympathomimetic agonists and antagonists on mucociliary activity. Acta Otolaryngol 94 (1982) 121-130
40. Hybbinette J.C., and Mercke U. Effects of the parasympathomimetic drug methacholine and its antagonist atropine on mucociliary activity. Acta Otolaryngol 93 (1982) 465-473
41. Foster W.M., Bergofsky E.H., Bohning D.E., Lippmann M., and Albert R.E. Effect of adrenergic agents and their mode of action on mucociliary clearance in man. J Appl Physiol 41 (1976) 146-152
42. Camner P., Strandberg K., and Philipson K. Increased mucociliary transport by cholinergic stimulation. Arch Environ Health 29 (1974) 220
43. Hasani A., Agnew J.E., Pavia D., Vora H., and Clarke S.W. Effect of oral bronchodilators on lung mucociliary clearance during sleep in patients with asthma. Thorax 48 (1993) 287-289
44. Messina M.S., O'Riordan T.G., and Smaldone G.C. Changes in mucociliary clearance during acute exacerbations of asthma. Am Rev Respir Dis 143 (1993) 993-997
45. Pavia D., Bateman J.R.M., Sheahan N.F., Agnew J.E., and Clarke S.W. Tracheobronchial mucociliary clearance in asthma: impairment during remission. Thorax 40 (1985) 175
46. Foster W.M., Langenback E.G., and Bergofsky E.H. Lung mucociliary function in man: inter-dependence of bronchial and tracheal mucus transport velocities with lung clearance in bronchial asthma and healthy subjects. Ann Occup Hyg 26 (1982) 227-244
47. Wanner A., Salathe M., and O'Riordan T.G. Mucociliary clearance in the airways. Am J Respir Crit Care Med 154 (1996) 1868-1902
48. Camner P., Mossberg B., and Philipson K. Tracheobronchial clearance and chronic obstructive lung disease. Scand J Respir Dis 54 (1973) 272-281
49. Vastag E., Matthys H., Zsamboki G., and Kohler D. Mucociliary clearance in smokers. Eur J Respir Dis 68 (1986) 107-113
50. Laurenco R.V., Klimek M.F., and Borowski C.J. Deposition and clearance of 2 μm particles in the tracheobronchial tree of normal subjects-smokers and nonsmokers. J Clin Invest 50 (1971) 1411-1420
51. Goodman R.M., Yergin B.M., Landa J.F., Golinvaux M.H., and Sackner M.A. Relationship of smoking history and pulmonary function tests to tracheal mucous velocity in nonsmokers, young smokers, ex-smokers and patients with chronic bronchitis. Am Rev Respir Dis 117 (1978) 205-214
52. Pavia D., Agnew J.E., Sutton P.P., Lopez-Vidriero M.T., Clay M.M., Killip M., et al. Effect of terbutaline administered from metered dose inhaler (2 mg) and subcutaneously (0.25 mg) on tracheobronchial clearance in mild asthma. Br J Dis Chest 81 (1987) 361-370
53. Sackner M.A. Effect of respiratory drugs on mucociliary clearance. Chest 73 (1978) 958-966
54. Lindberg S., Khan R., and Runer T. The effects of formoterol, a long-acting beta2-adrenoceptor agonist, on mucociliary activity. Eur J Pharmacol 285 (1995) 275-280
55. Melloni B., and Germouty J. The influence on mucociliary function of formoterol: a new beta-agonist. Rev Malad Respir 9 (1992) 503-507
56. Sackner M.A., Reinhart M., and Arkin B. Effects of beclomethasone dipropionate on tracheal mucous velocity. Am Rev Respir Dis 115 (1977) 1069-1070
57. Duchateau G.S., Zuidema J., and Merkus F.W. The in vitro and in vivo effect of a new non-halogenated corticosteroid-budesonide aerosol on human ciliary epithelial function. Allergy 41 (1986) 260-265
58. Agnew J.F., Bateman J.R.M., Pavia D., and Clarke S.W. Peripheral airways mucous clearance in stable asthma is improved by oral glucocorticoid therapy. Bull Eur Physiopathol Respir 20 (1984) 295-301
59. Puchelle E., Zahm J.M., Girard F., Bertrand A., Polu J.M., Aug F., et al. Mucociliary transport in vivo and in vitro. Relations to sputum properties in chronic bronchitis. Eur J Respir Dis 61 (1980) 254-264
60. Tronde A., Norden B., Marchner H., Wendel A.K., Lennernås H., and Bengtsson U.H. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci 92 (2003) 1216-1233
61. Tronde A., Norden B., Jeppsson A.B., Brunmark P., Nilsson E., Lennernås H., et al. Drug absorption from the isolated perfused rat lung-correlations with drug physicochemical properties and epithelial permeability. J Drug Target 11 (2003) 61-74
62. Geiser M., Gerber P., Maye I., Im Hof V., and Gehr P. Retention of Teflon particles in hamster lungs: a stereological study. J Aerosol Med 13 (2000) 43-55
63. Geiser M., Schürch S., and Gehr P. Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer. J Appl Physiol 94 (2003) 1793-1801
64. John J., Wollmer P., Dahlbäck M., Luts A., and Jonson B. Tidal volume and alveolar clearance of insoluble particles. J Appl Physiol 76 (1994) 584-588
65. Lay J.C., Stang M.R., Fisher P.E., Yakanskas J.R., and Bennett W.D. Airway retention of materials of different solubility following local intrabronchial deposition in dogs. J Aerosol Med 16 (2003) 153-166
66. Högger P., and Rohdewald P. Glucocorticoid receptors and fluticasone propionate. Rev Contemp Pharmacother 9 (1998) 501-522
67. Miller-Larsson A., Axelsson B.-O., Brattsand R., Edsbäcker S., and Ingelf J. Variable lipophilicity of budesonide: comparison with fluticasone propionate, mometasone furoate, and ciclesonide. Eur Respir J 22 Suppl 45 (2003) 33s
68. Davies N.M., and Feddah M.R. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 255 (2003) 175-187
69. Olsson B. Careful deposition modelling is needed to supplement human experiments. In: Proceedings of the respiratory drug delivery IX meeting, April 25-29, 2004. Desert Springs, CA. p. 195-202.
70. Lee P.S., Gerrity T.R., Hass F.J., and Lourenco R.V. A model for tracheobronchial clearance of inhaled particles in man and a comparison with data. IEEE Trans Biomed Eng 26 (1979) 624-630
71. Harrison T.W. Systemic availability of inhaled budesonide and fluticasone propionate. Healthy versus asthmatic lungs. Biodrugs 15 (2001) 405-411
72. Todd G.R., Acerini C.L., Buck J.J., Murphy N.P., Ross-Russell R., Warner J.T., et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J 19 (2002) 1207-1209
73. Whelan G.J., Blumer J.L., Martin R.J., Szefler S.J., Chinchilli V.M., Kraft M., et al. Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration. J Allergy Clin Immunol 116 (2005) 525-530
74. Schuh S., Reisman J., Alshehri M., Dupuis A., Corey M., Arseneault R., et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 343 (2000) 689-694
75. Hvizdos K.M., and Jarvis B. Budesonide inhalation suspension. A review on its use in infants, children and adults with inflammatory respiratory disorders. Drugs 60 (2000) 1141-1178
76. Volovitz B. Inhaled budesonide in the management of acute worsenings and exacerbations of asthma: a review of the evidence. Respir Med 101 (2007) 685-695
77. Roorda R.J., and Walhof C.M. Effects of inhaled fluticasone propionate administered with metered dose inhaler and spacer in mild to moderate croup: a negative preliminary report. Pediatr Pulmonol 25 (1998) 114-117
78. Keeley D. Higher dose inhaled corticosteroids in childhood asthma-What we do doesn't work and what we don't do does. Br Med J 322 (2001) 504-505
79. McKean M., and Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2 (2000) CD001107
80. 1 and AM PEFR to the same extent as twice-daily MF in patients with moderate persistent asthma. Eur Respir J 14 Suppl 30 (1999) 1s
81. Kemp J.P., Berkowitz R.B., Miller S.D., Murray J.J., Nolop K., and Harrison J E. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 106 (2000) 485-492
82. Postma D.S., Sevette C., Martinat Y., Schlösser N., Aumann J., and Kafé H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 17 (2001) 1083-1088
83. Selroos O., Edsbäcker S., and Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma 41 (2004) 771-790
84. Jones A.H., Langdon C.G., Lee P.S., Lingham S.A., Nankani J.P., Follows R.M., et al. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med 88 (1994) 293-299